Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Overview
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Companies Involved in Therapeutics Development
Cellid Co Ltd
PDC Line Pharma SAS
Scancell Holdings Plc
Vault Pharma Inc
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Drug Profiles
BVAC-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target GP100 for Melanoma and Non Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDC-mel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCIB-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Dormant Products
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Discontinued Products
Melanocyte Protein PMEL (ME20M or Melanocyte Protein Pmel 17 or Melanocytes Lineage Specific Antigen GP100 or Melanoma Associated ME20 Antigen or P1 or P100 or Premelanosome Protein or Silver Locus Protein Homolog or PMEL) - Product Development Milestones
Featured News & Press Releases
Aug 19, 2019: Update on the SCIB1 Phase 2 clinical trial in patients with advanced melanoma
Apr 25, 2019: Scancell announces UK regulatory approval to start SCIB1 phase 2 trial in patients with advanced melanoma
Oct 24, 2018: Scancell and Ichor provide update on SCIB1 Phase 2 clinical study in patients with advanced melanoma
Feb 12, 2018: Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients
Aug 29, 2017: Oncimmune and Scancell Present Data on use of Autoantibodies in Predicting Response to SCIB1 Immunotherapy
Jul 11, 2017: Continued progress on SCIB1 - eight patients reach 5 year survival milestone
Jun 26, 2017: Scancell Holdings Announces SCIB1 Patent Granted in Europe
Jan 03, 2017: Fil SCIB1 Phase 1/2 Clinical Study Report completed on schedule
Jul 21, 2016: Scancell Holdings Announces Leading D plasmid manufacturer Eurogentec appointed to manufacture new SCIB1 material
Jul 06, 2016: SCIB1 continues to deliver compelling survival data in melanoma
Jun 17, 2016: SCIB1 Drug Product Supply
Mar 23, 2016: Scancell’s SCIB1 ImmunoBody cancer vaccine being presented at the World Vaccine Congress
Jan 11, 2016: Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR? Companion Diagnostic
Oct 20, 2015: Translating innovative science into ground-breaking new products
Sep 16, 2015: ImmunoBody Presentation at Cancer vaccines Conference in London
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Cellid Co Ltd, H2 2019
Pipeline by PDC Line Pharma SAS, H2 2019
Pipeline by Scancell Holdings Plc, H2 2019
Pipeline by Vault Pharma Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019